In this In Focus, we will explore the latest developments and emerging concepts in the field of hematologic malignancies.
Browsing: precision medicine
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.
An Ontario-led international clinical trial has determined a new standard of care for patients with localized prostate cancer.
In this article the authors discuss how extensive biobanking for each individual patient with subsequent genome sequencing can open novel horizons for precision medicine in breast cancer.
Researchers have demonstrated the importance of testing for genetic abnormalities when deciding on treatment and diagnostic approaches for pediatric brain tumors.
This review will discuss the mechanisms of chemotherapeutic resistance learned from cell culture analysis and evaluate the use of in vitro models of resistance as a means to better understand and target cancer cells. Although this review will emphasize breast cancer, the future of medicine lies in a direction that forces us to consider all cancer types.
Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics
In this article from Personalized Medicine, you can read further about strategies for biomarker discovery and multilevel diagnostic panels for treatment optimization.
Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization
Read further about innovative concepts for the personalization of selective internal radiation therapy in treatment of hepatocellular carcinoma. This review explores how these methods could improve individual outcomes and reduce treatment-related complications.
A clinical trial carried out in a diverse set of advances cancers is the first to demonstrate that use of precision medicine can slow down tumor regrowth.
In this article, the authors outline their expectations for growth in RNA-based cancer diagnostics, particularly in immune oncology, and argue that those same forces that brought DNA sequencing into clinical laboratories – falling sequencing costs and a rapidly growing list of actionable markers – will lead to emergence of clinical RNA sequencing, despite the challenges.